LRRC18 activators encompass a diverse array of chemical compounds that modulate cellular signaling pathways, which in turn may influence the activity of the protein LRRC18. These activators vary in their mechanisms of action, some directly interacting with signaling molecules, while others affect the intracellular environment in a way that indirectly impacts LRRC18. For instance, forskolin, acting through adenylyl cyclase, raises cAMP levels to activate PKA, which may then phosphorylate and modulate LRRC18's activity. On the other hand, calcium modulators like A23187 and ionomycin directly increase intracellular calcium, a secondary messenger involved in many cellular processes, which could affect LRRC18 through calcium-dependent protein kinases. BAPTA and EGTA serve as calcium chelators, offering an inverse approach by buffering calcium levels, potentially altering LRRC18's state through the adjustment of calcium-mediated signaling.
The chemical class is further characterized by the inclusion of compounds such as IBMX, which prevents cAMP degradation, maintaining an environment conducive to PKA activation, and thapsigargin, which disrupts calcium storage, increasing cytosolic calcium concentration. KN-93 and nifedipine, though not direct activators, contribute to the class by modulating the activity of kinases and ion channels, respectively, thus influencing signaling pathways that could cascade down to affect LRRC18 function. The specific biochemical interactions of these LRRC18 activators highlight the intricate web of cellular signaling, where the modulation of second messengers and enzyme activities converge to regulate the functional state of proteins such as LRRC18 within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, which increases intracellular cAMP levels, potentially modulating LRRC18 activity through cAMP-dependent protein kinase A (PKA) phosphorylation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX, a non-selective phosphodiesterase inhibitor, maintains elevated cAMP levels, which may enhance LRRC18 activity through PKA-mediated pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), potentially leading to phosphorylation of proteins and downstream signaling effects that could alter LRRC18 functionality. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
Calcimycin (A23187) increases intracellular calcium, potentially activating calcium-dependent protein kinases and impacting LRRC18 activity. | ||||||
BAPTA, Free Acid | 85233-19-8 | sc-201508 sc-201508A | 100 mg 500 mg | $67.00 $262.00 | 10 | |
BAPTA, a calcium chelator, buffers calcium fluctuations, indirectly affecting calcium-sensitive pathways and potentially modulating LRRC18 function. | ||||||
EGTA | 67-42-5 | sc-3593 sc-3593A sc-3593B sc-3593C sc-3593D | 1 g 10 g 100 g 250 g 1 kg | $20.00 $62.00 $116.00 $246.00 $799.00 | 23 | |
EGTA, a calcium chelator like BAPTA, may impact LRRC18 by altering calcium-dependent signaling processes. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits SERCA, leading to increased cytosolic calcium concentration, which could affect proteins like LRRC18. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin, a calcium ionophore, raises intracellular calcium levels and may influence LRRC18 activity through calcium-dependent signaling. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
Dibutyryl-cAMP, a cAMP analog, activates PKA and could modulate LRRC18 activity by bypassing receptor-mediated pathways. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
KN-93 selectively inhibits CaMKII, which by modulating its activity, could indirectly affect the function of proteins like LRRC18. | ||||||